The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

BACKGROUND: At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their availability...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Uzma, Huerga, Helena, Khan, Aamir J., Mitnick, Carole D., Hewison, Catherine, Varaine, Francis, Bastard, Mathieu, Rich, Michael, Franke, Molly F., Atwood, Sidney, Khan, Palwasha Y., Seung, Kwonjune J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701145/
https://www.ncbi.nlm.nih.gov/pubmed/31429722
http://dx.doi.org/10.1186/s12879-019-4378-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701145/
https://www.ncbi.nlm.nih.gov/pubmed/31429722
http://dx.doi.org/10.1186/s12879-019-4378-4

Ejemplares similares